Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Drops By 35.8%

Neuronetics, Inc. (NASDAQ:STIM) saw a large decline in short interest in December. As of December 31st, there was short interest totalling 312,900 shares, a decline of 35.8% from the December 15th total of 487,400 shares. Based on an average daily volume of 413,300 shares, the short-interest ratio is presently 0.8 days. Approximately 2.0% of the company’s stock are sold short.

Hedge Funds Weigh In On Neuronetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STIM. First Washington CORP increased its holdings in shares of Neuronetics by 88.8% in the 2nd quarter. First Washington CORP now owns 1,274,540 shares of the company’s stock worth $2,294,000 after purchasing an additional 599,455 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in Neuronetics by 33.4% in the 2nd quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock worth $1,870,000 after buying an additional 260,000 shares in the last quarter. Renaissance Technologies LLC raised its position in Neuronetics by 124.5% in the 2nd quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock worth $580,000 after buying an additional 178,700 shares during the last quarter. HighTower Advisors LLC lifted its stake in Neuronetics by 55.5% during the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock valued at $187,000 after acquiring an additional 87,816 shares during the period. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of Neuronetics in the third quarter worth approximately $53,000. 53.59% of the stock is owned by institutional investors.

Neuronetics Stock Down 2.1 %

NASDAQ:STIM traded down $0.05 on Thursday, reaching $2.28. 537,118 shares of the stock traded hands, compared to its average volume of 1,490,912. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. The company has a market capitalization of $69.20 million, a price-to-earnings ratio of -1.85 and a beta of 2.11. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.07. The company’s fifty day simple moving average is $1.25 and its 200 day simple moving average is $1.22.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.